Lotta Kangasniemi

Biochemistry, Genetics and Molecular Biology · Life Sciences

23h-index2.2kcitations85works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Virus-based gene therapy research(85), Cancer Research and Treatments(66), CAR-T cell therapy research(45), Viral Infectious Diseases and Gene Expression in Insects(34), RNA Interference and Gene Delivery(10)

Publications85 total

Supplementary Figure Legend from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Data from Oncolytic Adenovirus ICOVIR-7 in Patients with Advanced and Refractory Solid Tumors
2023Open Access
Supplementary Figure 1 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Table 2 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Figure 4 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Table 3 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Figure 4 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Figure 1 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Figure Legend from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Figure 2 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Table 1 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Figure 2 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Data from Oncolytic Adenovirus ICOVIR-7 in Patients with Advanced and Refractory Solid Tumors
2023Open Access
Supplementary Figure 5 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Data from Oncolytic Adenovirus ICOVIR-7 in Patients with Advanced and Refractory Solid Tumors
2023Open Access
Supplementary Figure 3 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Figure 5 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Table 2 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Data from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Table 3 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Akseli Hemminki(50), Anna Kanerva(43), Vincenzo Cerullo(34), Leena Laasonen(29), Iulia Diaconu(27), Minna Oksanen(27), Petri Nokisalmi(23), Kaarina Partanen(21), Saila K. Pesonen(21), Anniina Koski(18), Elina Haavisto(18), Mari Raki(17), Timo Joensuu(17), Sophie Escutenaire(16), Kalevi Kairemo(16), Aila Karioja‐Kallio(15), Tuuli Ranki(14), Tuomo Alanko(14), Sari Pesonen(14), Sari Pesonen(13)